Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

Arrowhead Pharmaceuticals  / Equity Bottom-Up

<ul>
<li>Arrowhead Pharmaceuticals is committed to rapidly innovating and developing treatments and plans to grow their pipeline of RNAi therapeutics to a minimum of 20 clinical-stage or marketed products by the year 2025.</li>
<li>This pledge reflects Arrowhead's two core goals of maximizing the number of patients aided and the ability to generate enduring value for shareholders.</li>
<li>Due to the company's maturing pipeline, Arrowhead is focusing on prioritizing and investing in their internal programs and is actively building late-stage development and commercial infrastructure to focus on the cardiometabolic vertical.</li>
</ul>


Arrowhead Pharmaceuticals is committed to rapidly innovating and developing treatments and plans to grow their pipeline of RNAi therapeutics to a minimum of 20 clinical-stage or marketed products by the year 2025.
This pledge reflects Arrowhead's two core goals of maximizing the number of patients aided and the ability to generate enduring value for shareholders.
Due to the company's maturing pipeline, Arrowhead is focusing on prioritizing and investing in their internal programs and is actively building late-stage development and commercial infrastructure to focus on the cardiometabolic vertical.


Arrowhead Pharmaceuticals: Progression of ARO-MUC5AC & ARO-MMP7 Programs & Other Major Drivers

Equity Long-Short Analyst

Pyari Menon

Thematic (Sector/Industry)

<ul>
<li>2021 saw a significant jump in RNA based trials. Large sequencing projects and the success of mRNA COVID-19 vaccines should drive the growth of the global RNA therapeutics market. </li>
<li>Our analysis suggests that <a href="https://www.smartkarma.com/entities/moderna-inc" target="_blank" data-smartkarma-citation="entities:28744:1" rel="noopener">Moderna Inc (MRNA US)</a> , <a href="https://www.smartkarma.com/entities/vertex-pharmaceuticals-inc" target="_blank" data-smartkarma-citation="entities:4864:1" rel="noopener">Vertex Pharmaceuticals (VRTX US),</a> <a href="https://www.smartkarma.com/entities/incyte-corp" target="_blank" data-smartkarma-citation="entities:20576:1" rel="noopener">Incyte Corp (INCY US), </a><a href="https://www.smartkarma.com/entities/alnylam-pharmaceuticals-inc" target="_blank" data-smartkarma-citation="entities:2191:1" rel="noopener">Alnylam Pharmaceuticals (ALNY US), </a><a href="https://www.smartkarma.com/entities/isis-pharmaceuticals-inc" target="_blank" data-smartkarma-citation="entities:7017:1" rel="noopener">Ionis Pharmaceuticals (IONS US)</a> lead in RNA therapy related innovations.</li>
<li>R&amp;D collaboration, licensing deals, strategic investments and buyouts between RNA specialists and big pharma will increase as sitting on the sidelines might no longer be an option.</li>
</ul>


2021 saw a significant jump in RNA based trials. Large sequencing projects and the success of mRNA COVID-19 vaccines should drive the growth of the global RNA therapeutics market. 
Our analysis suggests that Moderna Inc (MRNA US) , Vertex Pharmaceuticals (VRTX US), Incyte Corp (INCY US), Alnylam Pharmaceuticals (ALNY US), Ionis Pharmaceuticals (IONS US) lead in RNA therapy related innovations.
R&amp;D collaboration, licensing deals, strategic investments and buyouts between RNA specialists and big pharma will increase as sitting on the sidelines might no longer be an option.


Data Mining Technical Publications to Rank the Innovators in RNA Therapeutics

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

<ul>
<li>The development trajectory of Japanese pharmaceutical companies could be a good reference for Chinese pharmaceutical companies. Their “solution” is innovation + internationalization.</li>
<li>We further analyzed the impact of Shanghai lockdown to Pharma and CXOs. In the context of intensifying global confrontation, resource shortage and soaring costs, the priority of healthcare may decline.</li>
<li>At the current stage, biotech companies could be divided into the following categories, and it is very interesting.</li>
</ul>


The development trajectory of Japanese pharmaceutical companies could be a good reference for Chinese pharmaceutical companies. Their “solution” is innovation + internationalization.
We further analyzed the impact of Shanghai lockdown to Pharma and CXOs. In the context of intensifying global confrontation, resource shortage and soaring costs, the priority of healthcare may decline.
At the current stage, biotech companies could be divided into the following categories, and it is very interesting.


China Healthcare Weekly (Apr.29)-SH Lockdown Impact on Pharma/CXO,China Biotech Categories & Way Out

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

<p>We remain concerned about the prospect for additional weakness for the broad market due to deterioration in several metrics that we often turn to to get a pulse on the market. At the same time, several cyclical areas of the market have bounced off of logical support while RS has been unable to break out to new highs for defensive Sectors. Absent bearish price inflections in the cyclicals and new RS highs for defensive areas of the market, equities are likely to remain in a state of purgatory.  In today’s report we highlight attractive Groups and stocks within Consumer Staples, Health Care, and Utilities.</p>

We remain concerned about the prospect for additional weakness for the broad market due to deterioration in several metrics that we often turn to to get a pulse on the market. At the same time, several cyclical areas of the market have bounced off of logical support while RS has been unable to break out to new highs for defensive Sectors. Absent bearish price inflections in the cyclicals and new RS highs for defensive areas of the market, equities are likely to remain in a state of purgatory.  In today’s report we highlight attractive Groups and stocks within Consumer Staples, Health Care, and Utilities.

U.S. Equity Strategy: Market Still Susceptible

<p>The S&amp;P 500 is poised to retest the 2,790-2,800 horizontal resistance level that we have highlighted in previous reports. A bullish short-term reversal in the XLF has helped bolster optimism in U.S. equities.  We continue to expect the broad YTD consolidation to continue, especially given heightened trade tariff tensions. In today’s report we highlight attractive opportunities within Consumer Staples, Technology, and Health Care.</p>

The S&amp;P 500 is poised to retest the 2,790-2,800 horizontal resistance level that we have highlighted in previous reports. A bullish short-term reversal in the XLF has helped bolster optimism in U.S. equities.  We continue to expect the broad YTD consolidation to continue, especially given heightened trade tariff tensions. In today’s report we highlight attractive opportunities within Consumer Staples, Technology, and Health Care.

U.S. Equity Strategy: XLF Support Holding; Large-Cap Health Care Perks Up

United States

Arrowhead Pharmaceuticals, Inc. operates as a biotechnology company. The Company develops medicines that treat intractable diseases by silencing the genes. Arrowhead Pharmaceuticals offers its services in the United States.

Arrowhead Pharmaceuticals (ARWR US)

Arrowhead Pharmaceuticals: Progression of ARO-MUC5AC & ARO-MMP7 Programs & Other Major Drivers

Arrowhead Pharmaceuticals is committed to rapidly innovating and developing treatments and plans to grow their pipeline of RNAi therapeutics to a...

Baptista Research

Data Mining Technical Publications to Rank the Innovators in RNA Therapeutics

Specialists lead the RNA intellectual property ecosystem but may still need big pharma to bring new treatments to market making the space ripe for...

Pyari Menon

China Healthcare Weekly (Apr.29)-SH Lockdown Impact on Pharma/CXO,China Biotech Categories & Way Out

We analyzed the impact of lockdown to Pharma and CXO, worrying the priority of healthcare may decline.China biotech can be divided into some...

Xinyao (Criss) Wang

U.S. Equity Strategy: Market Still Susceptible

We remain concerned about the prospect for additional weakness for the broad market due to deterioration in several metrics that we often turn to...

Vermilion Research

U.S. Equity Strategy: XLF Support Holding; Large-Cap Health Care Perks Up

The S&P 500 is poised to retest the 2,790-2,800 horizontal resistance level that we have highlighted in previous reports. A bullish short-term...

Vermilion Research